Researchers have reported the potency of IGF-1 LR3 peptide to be as much as 3x more than that of IGF-1 (1) , holding a potentially much greater half-life: roughly 20 to 30 hours, compared to the original IGF-1, which has a reported approximate 12 to 15 hours of half-life
Acute pancreatitis was reported in all 11 studies, with ARD values typically below 0.3% and overall event rates below 1%, suggesting no meaningful increase in risk compared with placebo
Lets look at this connection a bit more closely, and at the other health conditions where carnitine therapy has been investigated
GLP-1 medications do a lot of work in the body
Hypernatremia (due to the sodium content of valproic acid) or hyponatremia (due to valproic acid induced SIADH)
Injectable Therapeutic PeptidesAn Adjunct to Regenerative Medicine and Sports Performance